Citations

Clear

6273 citation(s) found for "To, Andrew".

Preoperative Dehydration does not Increase the Risk of Complications Following Elective Lumbar Surgery
Renfree, Sean P. , Chung, Andrew S. , Waldrop, Robert, Crandall, Dennis G. , Chang, Michael S. , Crandall, Dennis, Renfree, Sean , Chung, Andrew

Mayo Clinic

Spine | July 24, 2019 | Volume: 44 | Issue: 22 | Pages: E1336-E1341

10.1097/brs.0000000000003149 | PMID 31689256 Get It

Study Design. A retrospective cohort study. Objective. The aim of this study was to evaluate the effect of preoperative dehydration on hospital length of stay (LOS), rates of 30-day postoperative complications, related reoperations, and readmissions. Summary of Background Data. Preoperative dehydration has long been associated with postoperative infection, deep vein thrombosis (DVT), acute renal failure, and an increased hospital LOS. To our knowledge, the effect of preoperative dehydration on complication rates for patients undergoing elective lumbar spine surgery has not been well described. Methods. An analysis of American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) data from 2006 to 2013 was performed. Patients undergoing elective lumbar procedures were identified and exclusion criteria eliminated patients who underwent any emergency procedures, infections, tumor cases, or revision surgeries. Patient dehydration was defined as preoperative blood urea nitrogen/creatinine (BUN/Cr) ratio greater than 20. Results. Patients (4698; 34.5%) with preoperative dehydration based on BUN/Cr ratio were identified. Univariate analysis was suggestive of an association between preoperative dehydration and an increased risk of DVT (1.1% compared with 0.6%; P = 0.002), urinary tract infection (2.5% compared with 1.6%; P < 0.001), and need for transfusion postoperatively (17.6% compared with 14.4%; P < 0.001). However, on the basis of multivariate regression, no significant association between dehydration and increased odds of aforementioned outcomes was identified. Conclusion. Preoperative dehydration does not appear to negatively affect perioperative outcomes or readmission in patients undergoing elective lumbar spine surgery. Level of Evidence: 3
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Tam, Constantine S. , Opat, Stephen , Burger, Jan A. , Cull, Gavin , Gottlieb, David , Johnston, Patrick B. , Marlton, Paula , Seymour, John F. , Simpson, David , Tedeschi, Alessandra , Elstrom, Rebecca, Yu, Yiling , Tang, Zhiyu , Han, Lynn , Huang, Jane , Novotny, William , Wang, Lai, Roberts, Andrew W. , Trotman, Judith , Burger, Jan A , Seymour, John F , Simpson, David , Roberts, Andrew W , Tam, Constantine S , Opat, Stephen , Harrup, Rosemary Anne , Muñoz, Javier

Mayo Clinic

Blood | July 24, 2019 | Volume: 134 | Issue: 11 | Pages: 851-859

10.1182/blood.2019001160 | PMID 31340982 Get It

Abstract Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg once daily or 160 mg twice daily. Part 2 (expansion) consisted of disease-specific cohorts, including treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The primary end points were safety and tolerability, and definition of the maximum tolerated dose (part 1). Additional end points included pharmacokinetics/pharmacodynamics and preliminary efficacy. Reported herein are results from 144 patients enrolled in the dose-finding and CLL/SLL cohorts. No dose-limiting toxicities occurred in dose escalation. Median BTK occupancy in peripheral blood mononuclear cells was &gt;95% at all doses. Sustained complete (&gt;95%) BTK occupancy in lymph node biopsy specimens was more frequent with 160 mg twice daily than 320 mg once daily (89% vs 50%; P = .0342). Consequently, 160 mg twice daily was selected for further investigation. With median follow-up of 13.7 months (range, 0.4-30.5 months), 89 CLL/SLL patients (94.7%) remain on study. Most toxicities were grade 1/2; neutropenia was the only grade 3/4 toxicity observed in &gt;2 patients. One patient experienced a grade 3 subcutaneous hemorrhage. Among 78 efficacy-evaluable CLL/SLL patients, the overall response rate was 96.2% (95% confidence interval, 89.2-99.2). Estimated progression-free survival at 12 months was 100%. Zanubrutinib demonstrated encouraging activity in CLL/SLL patients, with a low incidence of major toxicities. This trial was registered at www.clinicaltrials.gov as #NCT02343120.
Clinical Efficacy of Liposomal Bupivacaine
Abildgaard, Jeffrey T. , Chung, Andrew S. , Tokish, John M. , Hattrup, Steven J. , Chung, Andrew

Mayo Clinic

JBJS Reviews | July 24, 2019 | Volume: 7 | Issue: 7 | Pages: e8-e8

10.2106/jbjs.rvw.18.00192 | PMID 31343508 Get It

Background: There has been a surge in interest with regard to the utility of liposomal bupivacaine as part of a perioperative pain management protocol. The current study was proposed to critically assess the efficacy of liposomal bupivacaine as a local anesthetic for pain relief following orthopaedic procedures. Methods: A systematic review of prospective, randomized trials involving liposomal bupivacaine was performed using searches of the PubMed, Embase, and Cochrane databases. The primary outcomes of interest included postoperative subjective pain scores and narcotic consumption. The length of stay and postoperative mobility were reviewed as secondary outcomes. Results: Twenty-seven studies met inclusion criteria and were included for review. Twelve of 17 studies concluded that periarticular or local infiltrative liposomal bupivacaine offered no additive benefit compared with other local anesthetic injections. Peripheral nerve blocks without liposomal bupivacaine conferred more optimal pain relief and decreased narcotic consumption in the immediate postoperative period when compared with liposomal bupivacaine, with no differences thereafter. Twelve studies listed a conflict of interest related to the drug manufacturer (Pacira Pharmaceuticals). Eight of these studies (67%) demonstrated clinical superiority of liposomal bupivacaine when compared with the study control. In the 15 studies that did not show a conflict of interest, only 1 study (7%) demonstrated therapeutic superiority with use of periarticular liposomal bupivacaine when compared with a historical cohort that received no local or regional anesthesia. Conclusions: Current prospective, randomized controlled trials in patients undergoing orthopaedic surgery fail to support the routine use of liposomal bupivacaine compared with other local injectable analgesics, particularly in the setting of knee replacement surgery. We were unable to find consistent support for the potential of superior pain relief and narcotic use reduction with the use of liposomal bupivacaine. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 24, 2019 | Volume: 200 | Issue: 9 | Pages: 1084-1085

10.1164/rccm.201907-1298ed | PMID 31339740 Get It

Type 8 long QT syndrome: pathogenic variants in CACNA1C-encoded Cav1.2 cluster in STAC protein binding site
Mellor, Greg , Panwar, Pankaj, Lee, Andrea K, Hathaway, Julie , Bartels, Kirsten , Balaji, Seshadri , Roberts, Jason D. , Simpson, Chris S., Boczek, Nicole J. , Tester, David J. , Radbill, Andrew E. , Mok, Ngai‐Shing, Hamilton, Robert M. , Kaufman, Elizabeth S. , Eugenio, Paul, January, Craig T., McDaniel, George, Leather, Richard, Falik, Shelley, Behr, Elijah R. , Wilde, Arthur A.M. , Sanatani, Shubhayan , Ackerman, Michael J. , Petegem, Filip Van , Laksman, Zachary , Behr, Elijah Raphael , Sanatani, Shubhayan , Hamilton, Robert , Steinberg, Christian , Christian, Susan , Weiss, Raul , Erickson, Christopher, Krahn, Andrew D.

Mayo Clinic

EP Europace | July 24, 2019 | Volume: 21 | Issue: 11 | Pages: 1725-1732

10.1093/europace/euz215 | PMID 31408100 Get It

Abstract Aims Pathogenic gain-of-function variants in CACAN1C cause type-8 long QT syndrome (LQT8). We sought to describe the electrocardiographic features in LQT8 and utilize molecular modelling to gain mechanistic insights into its genetic culprits. Methods and results Rare variants in CACNA1C were identified from genetic testing laboratories. Treating physicians provided clinical information. Variant pathogenicity was independently assessed according to recent guidelines. Pathogenic (P) and likely pathogenic (LP) variants were mapped onto a 3D modelled structure of the Cav1.2 protein. Nine P/LP variants, identified in 23 patients from 19 families with non-syndromic LQTS were identified. Six variants, found in 79% of families, clustered to a 4-residue section in the cytosolic II–III loop region which forms a region capable of binding STAC SH3 domains. Therefore, variants may affect binding of SH3-domain containing proteins. Arrhythmic events occurred in similar proportions of patients with II–III loop variants and with other P/LP variants (53% vs. 48%, P = 0.41) despite shorter QTc intervals (477 ± 31 ms vs. 515 ± 37 ms, P = 0.03). A history of sudden death was reported only in families with II–III loop variants (60% vs. 0%, P = 0.03). The predominant T-wave morphology was a late peaking T wave with a steep descending limb. Exercise testing demonstrated QTc prolongation on standing and at 4 min recovery after exercise. Conclusion The majority of P/LP variants in patients with CACNA1C-mediated LQT8 cluster in an SH3-binding domain of the cytosolic II–III loop. This represents a ‘mutation hotspot’ in LQT8. A late-peaking T wave with a steep descending limb and QT prolongation on exercise are commonly seen.
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer
Norden, Andrew D., Henk, Henry J. , Mansfield, Aaron S. , Arunajadai, Srikesh, Carnahan, Ryan M. , Christian, Jennifer , Torres, Aracelis Z. , Mansfield, Aaron S , Stewart, Mark D. , Dreyer, Nancy A , Abernethy, Amy P. , Chrischilles, Elizabeth A. , Kushi, Lawrence H. , Khozin, Sean , Sharon, Elad , Miksad, Rebecca Anne , Sakoda, Lori C. , Valice, Emily , Allen, Jeff D.

Mayo Clinic

JCO Clinical Cancer Informatics | July 23, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-15

10.1200/cci.18.00155 | PMID 31335166 Get It

PURPOSE This pilot study examined the ability to operationalize the collection of real-world data to explore the potential use of real-world end points extracted from data from diverse health care data organizations and to assess how these relate to similar end points in clinical trials for immunotherapy-treated advanced non–small-cell lung cancer. PATIENTS AND METHODS Researchers from six organizations followed a common protocol using data from administrative claims and electronic health records to assess real-world end points, including overall survival (rwOS), time to next treatment, time to treatment discontinuation (rwTTD), time to progression, and progression-free survival, among patients with advanced non–small-cell lung cancer treated with programmed death 1/programmed death-ligand 1 inhibitors in real-world settings. Data sets included from 269 to 6,924 patients who were treated between January 2011 and October 2017. Results from contributors were anonymized. RESULTS Correlations between real-world intermediate end points (rwTTD and time to next treatment) and rwOS were moderate to high (range, 0.6 to 0.9). rwTTD was the most consistent end points as treatment detail was available in all data sets. rwOS at 1 year post–programmed death-ligand 1 initiation ranged from 40% to 57%. In addition, rwOS as assessed via electronic health records and claims data fell within the range of median OS values observed in relevant clinical trials. Data sources had been used extensively for research with ongoing data curation to assure accuracy and practical completeness before the initiation of this research. CONCLUSION These findings demonstrate that real-world end points are generally consistent with each other and with outcomes observed in randomized clinical trials, which substantiates the potential validity of real-world data to support regulatory and payer decision making. Differences observed likely reflect true differences between real-world and protocol-driven practices.
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Stephens, Deborah M. , Li, Hongli , Straus, David J. , Moskowitz, Craig H. , Bartlett, Nancy L. , Evens, Andrew M. , LaCasce, Ann S. , Knopp, Michael V. , Leonard, John P. , Smith, Sonali M. , Friedberg, Jonathan W. , Bartlett, Nancy L , Evens, Andrew M , Stephens, Deborah M , Schöder, Heiko , LeBlanc, Michael , Rimsza, Lisa M. , Barr, Paul M. , Hsi, Eric D. , Kahl, Brad S.

Mayo Clinic

Blood | July 23, 2019 | Volume: 134 | Issue: 15 | Pages: 1238-1246

10.1182/blood.2019000719 | PMID 31331918 Get It

AbstractThe investigators present results on the long-term value and limitations of early interim positron emission tomography (PET) scanning in advanced Hodgkin lymphoma.
Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
Compton, Carolyn C. , Robb, James A., Anderson, Matthew W. , Berry, Anna B. , Birdsong, George , Bloom, Kenneth J., Branton, Philip A. , Crothers, Jessica W. , Cushman‐Vokoun, Allison M. , Hicks, David G., Khoury, Joseph D. , Laser, Jordan , Marshall, Carrie B. , Misialek, Michael J., Natale, Kristen E. , Nowak, Jan A. , Olson, Damon R. , Pfeifer, John D. , Schade, Andrew E., Vance, Gail H. , Walk, Eric , Yohe, Sophia , Birdsong, George G, Nowak, Jan Anthony, Olson, Damon, Schade, Andrew, Walk, Eric E, Yohe, Sophia Louise, Berry, Anna , Olson, Damon R

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 22, 2019 | Volume: 143 | Issue: 11 | Pages: 1346-1363

10.5858/arpa.2019-0009-sa | PMID 31329478 Get It

Biospecimens acquired during routine medical practice are the primary sources of molecular information about patients and their diseases that underlies precision medicine and translational research. In cancer care, molecular analysis of biospecimens is especially common because it often determines treatment choices and may be used to monitor therapy in real time. However, patient specimens are collected, handled, and processed according to routine clinical procedures during which they are subjected to factors that may alter their molecular quality and composition. Such artefactual alteration may skew data from molecular analyses, render analysis data uninterpretable, or even preclude analysis altogether if the integrity of a specimen is severely compromised. As a result, patient care and safety may be affected, and medical research dependent on patient samples may be compromised. Despite these issues, there is currently no requirement to control or record preanalytical variables in clinical practice with the single exception of breast cancer tissue handled according to the guideline jointly developed by the American Society of Clinical Oncology and College of American Pathologists (CAP) and enforced through the CAP Laboratory Accreditation Program. Recognizing the importance of molecular data derived from patient specimens, the CAP Personalized Healthcare Committee established the Preanalytics for Precision Medicine Project Team to develop a basic set of evidence-based recommendations for key preanalytics for tissue and blood specimens. If used for biospecimens from patients, these preanalytical recommendations would ensure the fitness of those specimens for molecular analysis and help to assure the quality and reliability of the analysis data.